Clinical Trials on Myeloproliferative Neoplasms

Total 107147 results

Sanofi

Completed

A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis

Myelofibrosis

United States
Masonic Cancer Center, University of Minnesota

Terminated

Cytosine Arabinoside and Mitoxantrone for Patients With Juvenile Myelomonocytic Leukemia Receiving Repeat Stem Cell Transplantation

Leukemia

United States
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI); Otsuka America Pharmaceutical

Completed

Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen (LCCC0510)

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm

United States
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm

United States
National Cancer Institute (NCI)

Completed

Interleukin-12 Followed by Interferon Alfa in Treating Patients With Advanced Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm | Precancerous Condition

United States
IRCCS Azienda Ospedaliero-Universitaria di Bologna

Completed

Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera (RAMP)

Adherence, Patient | Adherence, Treatment

Italy
Ohio State University Comprehensive Cancer Center

Active, not recruiting

Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study

Hematopoietic and Lymphoid Cell Neoplasm | Acute Myeloid Leukemia | Hodgkin Lymphoma | Myelofibrosis | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma | Myelodysplastic Syndrome | Plasma Cell Myeloma | Aplastic Anemia | Myeloproliferative Neoplasm | Chronic Myelogenous Leukemia...

United States
French Innovative Leukemia Organisation
Acute Leukemia French Association; French Intergroup of Myeloproliferative...

Recruiting

Evaluation of CPX-351 Monotherapy in Acute Myeloid Leukemia Secondary to Myeloproliferative Neoplasm (CPX-351 TA-SMP)

Acute Myeloid Leukemia | Myeloproliferative Syndrome

France
M.D. Anderson Cancer Center
Amgen

Terminated

Etanercept (Enbrel) for Juvenile Myelomonocytic Leukemia

Leukemia

United States
The Canadian Blood and Marrow Transplant Group
National Cancer Institute (NCI)

Completed

Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Graft Versus Host Disease | Secondary Myelofibrosis

Australia, Canada, United States, New Zealand, Saudi Arabia
Versailles Hospital

Completed

A Prospective Randomized Phase II Study Evaluating the Monitoring of Imatinib Mesylate Plasmatic Through Level in Patients Newly Diagnosed With CP-CML (OPTIMIMATINIB)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

France
Memorial Sloan Kettering Cancer Center
Eli Lilly and Company; Incyte Corporation

Recruiting

A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis

Myelofibrosis Due to and Following Polycythemia Vera

United States
Prelude Therapeutics

Terminated

PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies

Follicular Lymphoma | Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Myeloproliferative Neoplasm | Small Lymphocytic Lymphoma | B-cell Non-Hodgkin Lymphoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Decitabine in Treating Patients With Myelofibrosis

Primary Myelofibrosis | Secondary Myelofibrosis

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

P1101 in Treating Patients With Myelofibrosis

Primary Myelofibrosis | Secondary Myelofibrosis

United States
AbbVie

Active, not recruiting

A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis (REFINE)

Myelofibrosis (MF)

United States, Australia, Belgium, Bulgaria, Canada, Croatia, France, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Poland, Puerto Rico, Russian Federation, Serbia, Spain, Taiwan, Turkey, United Kingdom
Novartis Pharmaceuticals
Incyte Corporation

Terminated

A Study to Find the Maximum Tolerated Dose of the Experimental Combination of the Drugs INC424 and BKM120 in Patients With Primary or Secondary Myelofibrosis

Myelofibrosis

Spain, United Kingdom, Australia, Israel, Germany, Italy, Singapore, Austria, France
University of California, San Francisco

Completed

Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing MUD SCT

Multiple Myeloma | Non-Hodgkin's Lymphoma | Chronic Myeloid Leukemia | Acute Lymphocytic Leukemia | Acute Myelogenous Leukemia | Myelodysplasia | Severe Aplastic Anemia | Lymphoproliferative Disease | Advanced Myeloproliferative Disease

United States
Case Comprehensive Cancer Center

Completed

Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention

Acute Myeloid Leukemia | Multiple Myeloma | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma | Myelodysplastic Syndrome | Chronic Myelogenous Leukemia | Myeloproliferative Neoplasm | Acute Biphenotypic Leukemia | Hodgkins Disease

United States
University of Virginia

Completed

Effects of Prebiotics on Gut Microbiome in Patients Undergoing HSCT (HCTDiet)

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Multiple Myeloma | Hodgkin Disease | Hodgkin Lymphoma | Myelofibrosis | Acute Lymphoblastic Leukemia | Mantle Cell Lymphoma | Sickle Cell Disease | Non Hodgkin Lymphoma | Acute Lymphocytic Leukemia | Myeloproliferative Neoplasm

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy

Lymphoma | Leukemia | Breast Cancer | Chronic Myeloproliferative Disorders | Anemia | Small Intestine Cancer | Lung Cancer | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm | Precancerous Condition | Drug/Agent Toxicity by Tissue/Organ

United States, Canada
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Pyroxamide in Treating Patients With Advanced Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Small Intestine Cancer | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm | Precancerous Condition

United States
Asan Medical Center

Withdrawn

Extension Study of IDEAL (Imatinib) for Chronic Myelgenous Leukemia (CML) (IDEAL-E)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Korea, Republic of
University Hospital, Brest

Recruiting

Aprepitant Versus Hydroxyzine in Persistent Aquagenic Pruritus for Patients With Myeloproliferative Neoplasms (APHYPAP)

Myeloproliferative Disorder | Aquagenic Pruritus

France
M.D. Anderson Cancer Center
S*BIO

Completed

Study of SB939 in Subjects With Myelofibrosis

Myeloproliferative Disorders

United States
Northwestern University
National Cancer Institute (NCI); Celgene; The Leukemia and Lymphoma Society

Withdrawn

Durvalumab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis

Primary Myelofibrosis | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase

United States
Medical College of Wisconsin
Memorial Sloan Kettering Cancer Center; Dana-Farber Cancer Institute; University... and other collaborators

Completed

The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)

Leukemia, Myeloid, Chronic

United States
Bristol-Myers Squibb

Completed

Korean Post-marketing Surveillance for Sprycel®

Leukemia, Myelomonocytic, Chronic | Leukemia-Lymphoma

Korea, Republic of
Tehran University of Medical Sciences

Completed

Safety Assessment of a Multipeptide-gene Vaccine in CML

Leukemia, Myeloid, Chronic

Iran, Islamic Republic of
NCIC Clinical Trials Group

Completed

Treatment for Chronic Pain in Patients With Advanced Cancer

Pain | Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Small Intestine Cancer | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm | Precancerous/Nonmalignant Condition

Canada
Institut für Klinische Krebsforschung IKF GmbH...
Celgene International II S.á.r.l.; Prof. F. Heidel, MH Hannover

Recruiting

Fedratinib in Combination With Nivolumab

Primary Myelofibrosis | Secondary Myelofibrosis

Germany
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Ruxolitinib Phosphate and Chemotherapy Given Before and After Reduced Intensity Donor Stem Cell Transplant in Treating Patients With Myelofibrosis

Primary Myelofibrosis | Secondary Myelofibrosis

United States
M.D. Anderson Cancer Center
BreakThrough Therapeutics

Completed

Synthetic Vaccine in Patients With Chronic Myeloid Leukemia and Minimal Residual Disease

Chronic Myeloid Leukemia | Minimal Residual Disease

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients With Myelofibrosis

Primary Myelofibrosis | Anemia | Secondary Myelofibrosis

United States
Infinity Pharmaceuticals, Inc.

Completed

A Phase 2 Study With IPI-926 in Patients With Myelofibrosis

Primary Myelofibrosis | Fibrosis, Bone Marrow

United States
Northwestern University
National Cancer Institute (NCI)

Completed

Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Graft Versus Host Disease | Precancerous/Nonmalignant Condition

United States
First Affiliated Hospital of Harbin Medical University

Unknown

Evaluation of the Therapeutic Effect of HU Pulse Therapy for CML Patients (HU)

Leukemia, Chronic Myeloid

China
Agenus Inc.

Terminated

AG-858 in Patients Who Are Cytogenetically Positive After Treatment With Gleevec™

Leukemia, Myeloid, Chronic

United States, United Kingdom
King Faisal Specialist Hospital & Research Center

Unknown

Prospective Database for Chronic Myelogenous Leukemia

Leukemia, Myeloid, Chronic
Meng Li

Unknown

Safety and Efficiency Study of Pioglitazone in Combination With Imatinib Mesylate to Treat Chronic Myelogenous Leukemia (SESPI)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
University of Leipzig

Completed

Treatment of CML Patients With Imatinib and Hydroxyurea (CML2004) (CML2004)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
M.D. Anderson Cancer Center
Celgene

Completed

Pomalidomide for Myelofibrosis Patients

Polycythemia Vera | Thrombocythemia

United States
Novartis Pharmaceuticals

Terminated

A Study to Evaluate Safety and Efficacy of Panobinostat in Participants With Primary Myelofibrosis

Primary Myelofibrosis | Post-Polycythemia Vera | Post-Essential Thrombocytopenia

United States
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Completed

17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis

Lymphoma | Leukemia | Chronic Myeloproliferative Disorders | Precancerous Condition | Nonneoplastic Condition

United States
M.D. Anderson Cancer Center
Celgene Corporation

Completed

Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML)

Leukemia

United States
Indiana University School of Medicine
National Cancer Institute (NCI)

Completed

EMD 121974 in Treating Patients With Locally Advanced or Metastatic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Small Intestine Cancer | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm | Precancerous/Nonmalignant Condition

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Bone Marrow Transplantation in Treating Patients With Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Small Intestine Cancer | Multiple Myeloma and Plasma Cell Neoplasm | Precancerous/Nonmalignant Condition

United States
National Cancer Institute (NCI)

Completed

Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndromes

Recurrent Adult Acute Myeloid Leukemia | Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13... and other conditions

United States
Capital Research Institute of Pediatrics

Unknown

Modified Post-Transplant Cyclophosphamide Regimen for Children With Juvenile Myelomonocytic Leukemia

Hematopoietic System--Cancer

Clinical Trials on Myeloproliferative Neoplasms

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Taiwan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations